논문KCI 등재
Stabilizing hepatic fatty acid oxidation: Editorial on “USP29 alleviates the progression of MASLD by stabilizing ACSL5 through K48 deubiquitination”
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
참고문헌 (16)
관련 논문AI추천
USP29 alleviates the progression of MASLD by stabilizing ACSL5 through K48 deubiquitinationFang Qin, Hongjie Shi, Hongliang Li, Jianqing Zhang, Juanjuan Qin, Kun Zhu, Peng Zhang, Sha Hu, Song tian, Tuo Zhang, Xiaojing Zhang, Yanxiao Ji, Zhigang She, Zhouxiang Wang대한간학회 · Clinical and Molecular Hepatology2025 · 제31권 제1호TM6SF2 and PNPLA3: A potential dynamic duo?: Editorial on “TM6SF2 E167K variant decreases PNPLA3-mediated PUFA transfer to promote hepatic steatosis and injury in MASLD”Andrea Caddeo, Rosellina M. Mancina대한간학회 · Clinical and Molecular Hepatology2025 · 제31권 제1호PNPLA3 is one of the bridges between TM6SF2 E167K variant and MASLD: Correspondence to editorial on “TM6SF2 E167K variant decreases PNPLA3-mediated PUFA transfer to promote hepatic steatosis and injury in MASLD”Baokai Sun, Likun Zhuang대한간학회 · Clinical and Molecular Hepatology2025 · 제31권 제1호Ablation of the deubiquitinase USP15 ameliorates nonalcoholic fatty liver disease and nonalcoholic steatohepatitis이유진, Baek Jung-Hwan, Chung Joon-Yong, Chun Kyung-Hee, Han Dai Hoon, Hwang Ilseon, Hwang Min-Seon, Im Seung-Soon, Jung Hye Ryeon, Kim Kyungeun, Kim Myung Sup, Lee Chan-ho, Lee Yong-ho생화학분자생물학회 · Experimental and Molecular Medicine2023 · 제55권 Correspondence to editorial on “Macrophage ATG16L1 expression suppresses metabolic dysfunction-associated steatohepatitis progression by promoting lipophagy”Haoming Zhou, Ling Lu, Qingfa Bu, Qi Wang대한간학회 · Clinical and Molecular Hepatology2024 · 제30권 제4호Macrophage ATG16L1: Potential candidate for metabolic dysfunction-associated steatohepatitis treatment: Editorial on “Macrophage ATG16L1 expression suppresses metabolic dysfunction-associated steatohepatitis progression by promoting lipophagy”Junjie Yu대한간학회 · Clinical and Molecular Hepatology2024 · 제30권 제4호
이 간행물의 다른 논문 (84건)
Epidemiology of metabolic dysfunction-associated steatotic liver diseaseLinda Henry, Markos Kalligeros, Zobair M. Younossipp. 32-50Role of noninvasive tests in the prognostication of metabolic dysfunction-associated steatotic liver diseaseJimmy Che-To Lai, Sherlot Juan Song, Terry Cheuk-Fung Yip, Vincent Wai-Sun Wong, Grace Lai-Hung Wong, Yichong Jiang, Yue Wangpp. 51-75Precision medicine and nucleotide-based therapeutics to treat steatotic liver diseaseAndrea Caddeo, Stefano Romeopp. 76-93Microbiome-centered therapies for the management of metabolic dysfunction-associated steatotic liver diseaseJasmohan S. Bajaj, Jeremy Burton, Antonio Gil-Gómez, Huma Saeed, Juan Pablo Arab, Luis Antonio Díaz, Manuel Romero-Gomez, Marco Arrese, Mohammad Qasim Khanpp. 94-111Alcohol-associated liver disease: Natural history, management and novel targeted therapiesHugo López-Pelayo, Edilmar Alvarado-Tapias, Ana Clemente-Sánchez, Ramón Bataller, Jordi Gratacós-Ginès, Elisa Posepp. 112-133